Piclidenoson

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = N-methyl -2-[[4-(methyl amino)carbonyl]phenyl]ethyl]-1,3-dipropyl-8-phenylxanthine | image = Piclidenoson.svg | width = 250 | tradename = | legal_status = Investigational | routes_of_administration = Oral | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 152918-18-8 | ATC_prefix = none | PubChem = 3081365 | ChemSpiderID = 2338850 | UNII = 0F1Q2ZNR8N | KEGG = D08995 | ChEMBL = 2103870 | C=24 | H=31 | N=5 | O=3 | smiles = CCCn1c2c(c(=O)n(c1=O)CCC)c(n(c2=O)c3ccccc3)N(C)C(=O)c4ccc(cc4)N(C)C | InChI = 1S/C24H31N5O3/c1-5-14-29-21-19(22(31)28(23(29)32)15-6-3-4-7-16-15)25(13-14)20(30)17-8-10-18(11-9-17)26(2)24(33)27-12-26/h3-4,6-7,9-11,14H,5,8,12-13H2,1-2H3 | InChIKey = ZQZJXGJZQZJXGJ-UHFFFAOYSA-N }}

Piclidenoson is a small molecule drug that acts as a selective agonist for the adenosine A3 receptor. It is currently under investigation for its potential therapeutic effects in various inflammatory and autoimmune diseases, including rheumatoid arthritis and psoriasis.

Mechanism of Action

Piclidenoson exerts its effects by selectively binding to and activating the adenosine A3 receptor, a G protein-coupled receptor that is involved in modulating inflammatory responses. Activation of this receptor has been shown to lead to anti-inflammatory effects, which makes piclidenoson a promising candidate for the treatment of diseases characterized by chronic inflammation.

Clinical Development

Piclidenoson is being developed by Can-Fite BioPharma and has undergone several clinical trials to evaluate its safety and efficacy. In clinical studies, piclidenoson has demonstrated potential benefits in reducing symptoms of rheumatoid arthritis and psoriasis, with a favorable safety profile.

Rheumatoid Arthritis

In clinical trials for rheumatoid arthritis, piclidenoson has been shown to reduce disease activity and improve patient outcomes. The drug is being evaluated as a potential alternative to existing treatments, with the advantage of a different mechanism of action that may benefit patients who do not respond well to current therapies.

Psoriasis

For psoriasis, piclidenoson has been tested in patients with moderate to severe forms of the disease. Results from these studies suggest that piclidenoson can reduce the severity of skin lesions and improve quality of life for patients.

Pharmacokinetics

The pharmacokinetic profile of piclidenoson includes oral administration, with studies indicating good bioavailability and a half-life that supports once or twice daily dosing. The drug is metabolized in the liver and excreted primarily through the kidneys.

Safety and Tolerability

Piclidenoson has been generally well-tolerated in clinical trials, with a safety profile that compares favorably to other treatments for inflammatory diseases. Common side effects are mild and include headache, nausea, and fatigue.

Future Directions

Ongoing research is focused on further elucidating the therapeutic potential of piclidenoson in other inflammatory and autoimmune conditions. Additionally, studies are being conducted to better understand the long-term safety and efficacy of the drug.

Also see

• Adenosine receptor
• Rheumatoid arthritis treatment
• Psoriasis treatment
• Autoimmune disease